These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

340 related items for PubMed ID: 20384388

  • 1. Effects of oral contraceptives containing ethinylestradiol with either drospirenone or levonorgestrel on various parameters associated with well-being in healthy women: a randomized, single-blind, parallel-group, multicentre study.
    Kelly S, Davies E, Fearns S, McKinnon C, Carter R, Gerlinger C, Smithers A.
    Clin Drug Investig; 2010; 30(5):325-36. PubMed ID: 20384388
    [Abstract] [Full Text] [Related]

  • 2. Evaluation of the effect of a new oral contraceptive containing estetrol and drospirenone on hemostasis parameters.
    Douxfils J, Klipping C, Duijkers I, Kinet V, Mawet M, Maillard C, Jost M, Rosing J, Foidart JM.
    Contraception; 2020 Dec; 102(6):396-402. PubMed ID: 32956694
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of the combined oral contraceptive ethinylestradiol/drospirenone (Yasmin) in healthy Chinese women: a randomized, open-label, controlled, multicentre trial.
    Guang-Sheng F, Mei-Lu B, Li-Nan C, Xiao-Ming C, Zi-Rong H, Zi-Yan H, Xiao-Ping J, Jian L, Shu-Ying W, Cheng-Liang X, Zheng-Ai X, Tian-Fu Y.
    Clin Drug Investig; 2010 Dec; 30(6):387-96. PubMed ID: 20201608
    [Abstract] [Full Text] [Related]

  • 4. An open-label randomized comparative study of oral contraceptives between medications containing 3 mg drospirenone/30 microg ethinylestradiol and 150 microg levonogestrel/30 microg ethinylestradiol in Thai women.
    Suthipongse W, Taneepanichskul S.
    Contraception; 2004 Jan; 69(1):23-6. PubMed ID: 14720615
    [Abstract] [Full Text] [Related]

  • 5. Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism.
    Oelkers W, Foidart JM, Dombrovicz N, Welter A, Heithecker R.
    J Clin Endocrinol Metab; 1995 Jun; 80(6):1816-21. PubMed ID: 7775629
    [Abstract] [Full Text] [Related]

  • 6. Ethinylestradiol/drospirenone: a review of its use as an oral contraceptive.
    Keam SJ, Wagstaff AJ.
    Treat Endocrinol; 2003 Jun; 2(1):49-70. PubMed ID: 15871554
    [Abstract] [Full Text] [Related]

  • 7. [Individualization of low-dose oral contraceptives. Pharmacological principles and practical indications for oral contraceptives].
    Cianci A, De Leo V.
    Minerva Ginecol; 2007 Aug; 59(4):415-25. PubMed ID: 17923832
    [Abstract] [Full Text] [Related]

  • 8. A comparative study of monophasic oral contraceptives containing either drospirenone 3 mg or levonorgestrel 150 microg on premenstrual symptoms.
    Sangthawan M, Taneepanichskul S.
    Contraception; 2005 Jan; 71(1):1-7. PubMed ID: 15639064
    [Abstract] [Full Text] [Related]

  • 9. Comparative analysis of the effects of nomegestrol acetate/17 β-estradiol and drospirenone/ethinylestradiol on premenstrual and menstrual symptoms and dysmenorrhea.
    Witjes H, Creinin MD, Sundström-Poromaa I, Martin Nguyen A, Korver T.
    Eur J Contracept Reprod Health Care; 2015 Jan; 20(4):296-307. PubMed ID: 25712537
    [Abstract] [Full Text] [Related]

  • 10. Bleeding pattern and cycle control with an estradiol-based oral contraceptive: a seven-cycle, randomized comparative trial of estradiol valerate/dienogest and ethinyl estradiol/levonorgestrel.
    Ahrendt HJ, Makalová D, Parke S, Mellinger U, Mansour D.
    Contraception; 2009 Nov; 80(5):436-44. PubMed ID: 19835717
    [Abstract] [Full Text] [Related]

  • 11. A randomized study on the influence of oral contraceptives containing ethinylestradiol combined with drospirenone or desogestrel on lipid and lipoprotein metabolism over a period of 13 cycles.
    Gaspard U, Endrikat J, Desager JP, Buicu C, Gerlinger C, Heithecker R.
    Contraception; 2004 Apr; 69(4):271-8. PubMed ID: 15033400
    [Abstract] [Full Text] [Related]

  • 12. Experiences with Yasmin: the acceptability of a novel oral contraceptive and its effect on well-being.
    Mansour D.
    Eur J Contracept Reprod Health Care; 2002 Dec; 7 Suppl 3():35-41; discussion 42-3. PubMed ID: 12659405
    [Abstract] [Full Text] [Related]

  • 13. Multicenter, comparative study of cycle control, efficacy and tolerability of two low-dose oral contraceptives containing 20 microg ethinylestradiol/100 microg levonorgestrel and 20 microg ethinylestradiol/500 microg norethisterone.
    Endrikat J, Hite R, Bannemerschult R, Gerlinger C, Schmidt W.
    Contraception; 2001 Jul; 64(1):3-10. PubMed ID: 11535206
    [Abstract] [Full Text] [Related]

  • 14. A historical cycle control comparison of two drospirenone-containing combined oral contraceptives: ethinylestradiol 30 μg/drospirenone 3 mg administered in a 21/7 regimen versus ethinylestradiol 20 μg/drospirenone 3 mg administered in a 24/4 regimen.
    Marr J, Gerlinger C, Kunz M.
    Eur J Obstet Gynecol Reprod Biol; 2012 May; 162(1):91-5. PubMed ID: 22391750
    [Abstract] [Full Text] [Related]

  • 15. Unique effects on hepatic function, lipid metabolism, bone and growth endocrine parameters of estetrol in combined oral contraceptives.
    Mawet M, Maillard C, Klipping C, Zimmerman Y, Foidart JM, Coelingh Bennink HJ.
    Eur J Contracept Reprod Health Care; 2015 May; 20(6):463-75. PubMed ID: 26212489
    [Abstract] [Full Text] [Related]

  • 16. Maintaining physiological testosterone levels by adding dehydroepiandrosterone to combined oral contraceptives: I. Endocrine effects.
    Coelingh Bennink HJT, Zimmerman Y, Laan E, Termeer HMM, Appels N, Albert A, Fauser BCJM, Thijssen JHH, van Lunsen RHW.
    Contraception; 2017 Nov; 96(5):322-329. PubMed ID: 27393080
    [Abstract] [Full Text] [Related]

  • 17. Risk of venous thromboembolism and the use of dienogest- and drospirenone-containing oral contraceptives: results from a German case-control study.
    Dinger J, Assmann A, Möhner S, Minh TD.
    J Fam Plann Reprod Health Care; 2010 Jul; 36(3):123-9. PubMed ID: 20659364
    [Abstract] [Full Text] [Related]

  • 18. A comparison of cycle control with monophasic levonorgestrel/ethinylestradiol 100 micrograms/20 micrograms versus triphasic norethindrone/ethinylestradiol 500-750-1000 micrograms/35 micrograms: a multicenter, randomized, open-label study.
    Chavez A, DelConte A.
    Eur J Contracept Reprod Health Care; 1999 Jun; 4(2):75-83. PubMed ID: 10427482
    [Abstract] [Full Text] [Related]

  • 19. Effects of two combined oral contraceptives containing ethinyl estradiol 30 microg combined with either gestodene or drospirenone on hemostatic parameters, lipid profiles and blood pressure.
    Yildizhan R, Yildizhan B, Adali E, Yoruk P, Birol F, Suer N.
    Arch Gynecol Obstet; 2009 Aug; 280(2):255-61. PubMed ID: 19125264
    [Abstract] [Full Text] [Related]

  • 20. Endocrine and metabolic effects of an oral contraceptive containing estetrol and drospirenone.
    Klipping C, Duijkers I, Mawet M, Maillard C, Bastidas A, Jost M, Foidart JM.
    Contraception; 2021 Apr; 103(4):213-221. PubMed ID: 33428907
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.